The use of CAR enables T cells to recognize TAAs in an MHC-independent manner, hence overcoming defects in antigen processing and presentation mediated by tumor cells, one of the inhibitory mechanisms for initial tumor escape. The gene discussed is HLA-C; the disease is neoplasm.